NDA 213137 · Global Blood Theraps
Oxbryta
Voxelotor · Oral · Hemoglobin S Polymerization Inhibitor
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanDiscontinuedLast checked: Nov 20, 2026Latest source record: Aug 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Nov 25, 2019
Approved uses
2
Original approval plus efficacy supplements
Registered trials
27
6 Phase 3, 0 recruiting
FAERS reports
22,311
9,624 serious, 419 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 26, 2023.
OXBRYTA is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 4 years of age and older. This indication is approved under accelerated approval based on increase in hemoglobin (Hb) [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). OXBRYTA is a hemoglobin S polymerization inhibitor indicated for the treatment of sickle cell disease in adults and pediatric patients 4 years of age and older. This indication is approved under accelerated approval based on increase in hemoglobin (Hb). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). ( 1 )
Mechanism: Voxelotor is a hemoglobin S (HbS) polymerization inhibitor that binds to HbS with a 1:1 stoichiometry and exhibits preferential partitioning to red blood cells (RBCs). By increasing the affinity of Hb for oxygen, voxelotor demonstrates dose-dependent inhibition of HbS polymerization. Nonclinical studies suggest that voxelotor may inhibit RBC sickling, improve RBC deformability, and reduce whole blood viscosity.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 17, 2021 Supplement 6 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
- Nov 25, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
2 products under this application
- OXBRYTA · VOXELOTOR 300MG · TABLET, ORAL · Discontinued
- OXBRYTA · VOXELOTOR 500MG · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Voxelotor" as an intervention, any sponsor and status, largest first.
- Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE)Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT03036813 · 449 participants · Start Dec 2016 · Primary completion Oct 8, 2019
Drug: voxelotor · For: Sickle Cell Disease
Sites: Birmingham, Alabama; Mobile, Alabama; Little Rock, Arkansas · 62 sites in all
- Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell DiseasePivotal-lookingTerminated
PfizerPfizer (PFE)
NCT04218084 · 236 participants · Start Nov 11, 2020 · Primary completion Jan 18, 2024
Drug: Voxelotor; Placebo · For: Sickle Cell Disease
Sites: Washington D.C., District of Columbia; Miami, Florida; Atlanta, Georgia · 35 sites in all
- Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031Pivotal-lookingTerminated
PfizerPfizer (PFE)
NCT03573882 · 179 participants · Start Jun 6, 2018 · Primary completion Nov 12, 2024
Drug: Voxelotor · For: Sickle Cell Disease
Sites: Little Rock, Arkansas; Oakland, California; Miami, Florida · 60 sites in all
- Open-Label Extension of VoxelotorPivotal-lookingTerminated
PfizerPfizer (PFE)
NCT04188509 · 162 participants · Start Nov 18, 2019 · Primary completion Nov 1, 2024
Drug: Voxelotor · For: Sickle Cell Disease
Sites: Washington D.C., District of Columbia; Atlanta, Georgia; Chicago, Illinois · 20 sites in all
PfizerPfizer (PFE)
NCT02850406 · 147 participants · Start Jul 5, 2016 · Primary completion Oct 2, 2023
Drug: Voxelotor · For: Sickle Cell Disease
Sites: Brentwood, California; Washington D.C., District of Columbia; Atlanta, Georgia · 20 sites in all
- A Study of the Safety, Blood Levels and Biological Effects of GBT440 in Healthy Subjects and Subjects With Sickle Cell DiseasePivotal-lookingCompleted
Global Blood TherapeuticsIndustry
NCT02285088 · 133 participants · Start Dec 2014 · Primary completion Mar 2017
Drug: GBT440; Placebo · For: Healthy Subjects; Sickle Cell Disease
Sites: London, United Kingdom
- Resolution of Sickle Cell Leg Ulcers With VoxelotorPivotal-lookingTerminated
PfizerPfizer (PFE)
NCT05561140 · 88 participants · Start May 30, 2022 · Primary completion Jun 26, 2024
Drug: Voxelotor Oral Tablet · For: Sickle Cell Disease; Leg Ulcers
Sites: Salvador, Brazil; Belo Horizonte, Brazil; Recife, Brazil · 23 sites in all
PfizerPfizer (PFE)
NCT05981365 · 44 participants · Start Apr 17, 2023 · Primary completion Oct 4, 2023
Drug: Voxelotor; Bupropion and 7 more · For: Sickle Cell Disease
Sites: San Antonio, Texas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- sickle cell anaemia with crisis11,220
- product dose omission issue5,172
- diarrhoea3,187
- off label use2,419
- nausea2,017
- headache1,691
- abdominal pain upper1,171
- pain1,086
- therapy cessation1,040
- fatigue1,008
- abdominal discomfort970
- therapy interrupted901
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 3 |
| 2020 | 3,384 |
| 2021 | 3,536 |
| 2022 | 9,276 |
| 2023 | 4,504 |
| 2024 | 1,436 |
| 2025 | 142 |
| 2026 | 30 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Oxbryta (Voxelotor)
2024 spending
$77.2M
Beneficiaries
1,374
6,389 claims
Per beneficiary
$56,178
$134.18 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $47,599,743 |
| 2021 | $66,140,617 |
| 2022 | $77,713,365 |
| 2023 | $101,345,754 |
| 2024 | $77,189,159 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
Vichinsky E, Hoppe CC, Ataga KI, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Comparative Study
- Effect of voxelotor on cardiopulmonary testing in youths with sickle cell anemia in a pilot study.
Phan V, Hershenson J, Caldarera L, et al. · Pediatr Blood Cancer 2023 · Clinical Trial, Research Support, Non-U.S. Gov't
- Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease.
Han J, Saraf SL, Gordeuk VR · Pharmacotherapy 2020 · Systematic Review
- Modeling the public health impact of voxelotor in the management of sickle cell disease in France.
Galacteros F, Ethgen O, Beillat M · PLoS One 2023 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment.
Preston RA, Marbury T, Balaratnam G, et al. · J Clin Pharmacol 2021 · Clinical Trial, Research Support, N.I.H., Extramural
- The influence of voxelotor on cerebral blood flow and oxygen extraction in pediatric sickle cell disease.
Brothers RO, Turrentine KB, Akbar M, et al. · Blood 2024 · Clinical Trial, Research Support, Non-U.S. Gov't
Sponsor: Global Blood Theraps
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.